CELL INTELLIGENCE · 肿瘤细胞治疗研究

肠-肝-免疫轴：结构基础、细胞构筑、分子介质及疾病特异性表现

The gut-liver-immune axis: structural basis, cellular architecture, molecular mediators, and disease-specific manifestations.

移植前 NK 细胞活性可预测活体肝移植术后的生存与肿瘤复发

Pre-Transplant Natural Killer Cell Activity Predicts Survival and Tumor Recurrence After Living Donor Liver Transplantation.

不可逆电穿孔与 CAR-NK 细胞疗法对肝细胞癌的协同免疫治疗效果

Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma.

肝细胞癌的治疗策略：当前进展与未来展望

Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives.

肝细胞癌辅助细胞因子诱导的杀伤细胞免疫治疗：真实世界数据及一项随机对照试验的 9 年延长随访

Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized control

辅助 CIK 细胞治疗在 RWD 研究和 9 年扩展 RCT 随访中均显著改善 RFS，支持其在 HCC 根治性治疗后降低复发方面具有可重复的获益。这些一致的发现为 CIK 治疗作为 HCC 持久辅助免疫治疗策略的临床实用性提供了有力证据。

白细胞介素-32 在炎症性疾病和癌症中的多方面作用

Multifaceted role of interleukin-32 in inflammatory diseases and cancer.

肿瘤内皮细胞与淋巴细胞密度在接受免疫治疗的晚期肝细胞癌患者中的不同意义

Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapy.

HO-1197 作为一种多面性治疗药物：靶向肝细胞癌中的细胞周期、血管生成、转移和肿瘤免疫

HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma.

抑制 MCP1（CCL2）增强 NK 细胞在缺氧条件下对 HCC 细胞的抗肿瘤活性

Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia.

肝移植后超出米兰标准的肝细胞癌患者接受自体细胞因子诱导的杀伤细胞辅助免疫治疗的安全性和治疗结局

Safety and Therapeutic Outcomes of Adjuvant Immunotherapy With Autologous Cytokine-induced Killer Cells for Patients With Hepatocellular Carcinoma Bey

这些发现支持 CIK 疗法作为一种安全有效的潜在辅助治疗，用于移植后超出 Milan 标准的 HCC 患者，并支持进一步验证试验。